首页> 美国卫生研究院文献>Therapeutics and Clinical Risk Management >A new extended release formulation (OROS®) of hydromorphone in the management of pain
【2h】

A new extended release formulation (OROS®) of hydromorphone in the management of pain

机译:一种新的氢吗啡酮缓释制剂(OROS®)用于治疗疼痛

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Opioid analgesics are essential in the treatment of moderate to severe cancer-related pain. Opioids are also recognized as important in the management of other severe, persistent refractory painful conditions, such as sickle cell disease and arthritis. In the clinical practice of pain management, stable opioid dosing generally depends on achieving maximal analgesia with tolerable side effects typical of opioid analgesics. There is a wide interindividual variability of responsiveness to exogenous opioids both in terms of analgesic efficacy and side effects. Optimizing pain management for the individual patient may require sequential trials of opioid medications until the regimen with the most favorable therapeutic ratio of efficacy to side effects is determined.
机译:阿片类镇痛药对于中度至重度癌症相关性疼痛的治疗至关重要。阿片类药物也被认为在治疗其他严重,持续性难治性疼痛状况(例如镰状细胞病和关节炎)中很重要。在疼痛管理的临床实践中,稳定的阿片类药物剂量通常取决于获得最大的镇痛作用,并具有阿片类镇痛药典型的可耐受的副作用。就止痛功效和副作用而言,对外源阿片类药物的反应性存在很大的个体差异。优化单个患者的疼痛管理可能需要对阿片类药物进行序贯试验,直到确定出疗效与副作用最有利的治疗方案为止。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号